Collaboration

#Collaboration #Covid-19 #Mouse models #Research

Agreement paves the way for better mouse models to study Covid-19 

Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International are launching a new project to uncover how different cells in the human immune system respond to SARS-CoV-2, the virus that causes Covid-19.   The research  This new mouse model has been engineered… Read More

#Covid-19 #News

#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

Pfizer and BioNTech develop first mRNA-based shingles vaccine

Pfizer and BioNTech have announced a new research, development and commercialisation collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), which impacts about one in three people in the US during their lifetime.   Why now?  The collaboration… Read More

#News

#Collaboration #Laboratory of the Future

What does the lab of the future look like? 

Davy Petit, Senior Director of Global Pharmaceutical and Biomedical Research Business at Waters Corporation, spoke with Lu Rahman about how the life sciences industry can continue its momentum of developing life-changing drugs, therapeutics and solutions, as well as how organisations can ensure innovation and collaboration remain at the forefront as we enter into… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Bipolar #Collaboration #Drug development #Pharmaceuticals

Partnership meets an unmet need for bipolar disorder patients 

Lo.Li. Pharma International has announced a new strategic partnering plan for its new product, Deplesin, which meets an unmet need for bipolar disorder (BD) patients. The discussions are underway with the aim of increasing accessibility to this novel adjunctive agent in the treatment of BD patients, who often experience a number… Read More

#News

#Collaboration #Covid-19 #Research

Can this chewing gum reduce SARS-CoV-2 transmission? 

According to a new study, scientists have found chewing gum laced with a plant-grown protein serves as a “trap” for the SARS-CoV-2 virus, reducing viral load in saliva and potentially tamping down transmission.  The study  The work, led by Henry Daniell at the University of Pennsylvania’s School… Read More

#Covid-19 #News

#Collaboration #Drug development #Drug discovery #Genomics #Machine learning

GSK and Oxford University team up to unravel mechanisms of disease 

GlaxoSmithKline (GSK) and the University of Oxford have announced a five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine, which will be based at the University of Oxford and improve the success and speed of research and development of new medicines, building on insights from human… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Drug discovery

CGT Catapult’s creating opportunities in UK cell and gene therapy 

The Cell and Gene Therapy (CGT) Catapult has today published its Annual Review 2021, highlighting its key initiatives and impact in creating opportunities and investment in the UK cell and gene therapy industry.  2021 has reportedly emphasised the strength of the UK cell and gene therapy industry which experienced… Read More

#News

#Collaboration #Drug development #Funding

Benchling announces $100 million funding and continued expansion 

Benchling is continuing its European expansion, following a strong year of growth. This expansion comes as Benchling reveals it has raised $100 million in Series F funding at a $6.1 billion valuation.   Context  The company achieved triple-digit year-over-year revenue growth in the market in its most recent fiscal… Read More

#News

Handshake
#Autoimmune disease #Collaboration #Drug development #Drug targets #Funding #Partnership

Agreement to develop drug target for multiple autoimmune diseases 

Affibody partnered with ACELYRIN to develop and commercialise izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases.   Izokibep is an antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous… Read More

#News

#Collaboration #Covid-19 #Research

This week in drug discovery (15-19 November) 

News round-up by DDW’s Megan Thomas for 15-19 November  As the world emerges from the Covid-19 pandemic, DDW’s Megan Thomas has rounded up five stories which show how the drug discovery industry has used what it has learnt over the last two years to innovate for the… Read More

#News #Trending News

#Biology #Collaboration #Covid-19 #Research

CN Bio and iiCON announce Covid-19 research collaboration

CN Bio has entered a research collaboration with the Infection Innovation Consortium (iiCON) to validate the next generation of Covid-19 research tools.  iiCON’s £174 million programme brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and products. Led by the Liverpool School of… Read More

#Covid-19 #News #Trending News

#Collaboration #Drug discovery

This week in drug discovery (8-12 November) 

News round-up by DDW’s Megan Thomas for 8-12 November  DDW’s Megan Thomas has selected five stories which highlight the collaborative work being done across the drug discovery industry.  1. SAGA Diagnostics and AstraZeneca enter assay development agreement  SAGA Diagnostics, a cancer liquid… Read More

#News #Trending News

#Collaboration #Funding #Lead optimisation

Collaboration to develop oral targeted protein degrader therapies 

Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs.  Dunad will be responsible for programme execution up to lead optimisation, while Novartis will contribute target and ligand knowledge as well as access to assays… Read More

#News

#Cancer #Collaboration #Translational

Academic collaboration to develop therapies for genetic diseases and cancers 

BridgeBio has collaborated with two new academic institutions, Columbia University and Mount Sinai (Icahn Mount Sinai), to translate research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.  “Columbia University and Mount Sinai are known for bringing together some of the most talented scientists… Read More

#News

#Antibodies #Collaboration #Drug development #Drug discovery #Monoclonal antibodies

Nautilus and Abcam partner to accelerate proteome exploration  

Nautilus Biotechnology and Abcam have announced a strategic development and supply partnership to leverage Abcam’s recombinant monoclonal antibody development technologies and expertise to enhance Nautilus’ reagent research and development.   The partnership will initially focus on the collaborative development of affinity binding reagents for use on the… Read More

#News #Trending News

#CAR-T #Cell and gene therapy #Collaboration #Drug development #Drug discovery

Sitting down with… Julian Cole, Cell & Gene Collective 

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis.  LR: What was… Read More

#Editor's Choice #Exclusive Content #News #Opinion